Kelsey Goodwin
Stock Analyst at Guggenheim
(0)
# 4408
Out of 5,218 analysts
15
Total ratings
44.44%
Success rate
-10.68%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Genelux | Initiates Coverage On: Buy | 8 | 2.33 | 243.35% | 1 | Oct 29, 2024 | |
Nuvalent | Maintains: Strong Buy | 99 105 | 86.68 | 21.14% | 2 | Sep 16, 2024 | |
UroGen Pharma | Initiates Coverage On: Buy | 40 | 11.35 | 252.42% | 1 | Aug 22, 2024 | |
Macrogenics | Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 31, 2024 | |
2seventy bio | Downgrades: Neutral | n/a | n/a | n/a | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 15 | 1.22 | 1129.51% | 1 | Oct 31, 2022 |